Immunomodulation Therapies for Atherosclerosis: The Past, the Present, and the Future

Atherosclerotic cardiovascular disease is the most common cause of morbidity and death worldwide. Recent studies have demonstrated that this chronic inflammatory disease of the arterial wall can be controlled through the modulation of immune system activity. Many patients with cardiovascular disease remain at elevated risk of recurrent events despite receiving current, state-of-the-art preventive medical treatment. Much of this residual risk is attributed to inflammation. Therefore, finding new treatment strategies for this category of patients became of common interest. This review will discuss the experimental and clinical data supporting the possibility of developing immune-based therapies for lowering cardiovascular risk, explicitly focusing on vaccination strategies.

[1]  A. Thrift,et al.  Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial. , 2022, Atherosclerosis.

[2]  G. Sangiorgi,et al.  SARS-CoV-2 and Atherosclerosis: Should COVID-19 Be Recognized as a New Predisposing Cardiovascular Risk Factor? , 2021, Journal of cardiovascular development and disease.

[3]  J. Borén,et al.  Antibodies against apoB100 peptide 210 inhibit atherosclerosis in apoE-/- mice , 2021, Scientific Reports.

[4]  B. Amundsen,et al.  Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction. , 2021, Journal of the American College of Cardiology.

[5]  Amal J. Ali,et al.  Regulatory T Cell Stability and Plasticity in Atherosclerosis , 2020, Cells.

[6]  S. Kihara,et al.  Anti-Apo B-100 Autoantibody is a Marker of Unstable Coronary Plaque , 2020, Journal of atherosclerosis and thrombosis.

[7]  G. Hankey,et al.  Colchicine in Patients with Chronic Coronary Disease. , 2020, The New England journal of medicine.

[8]  K. Ley,et al.  T cell subsets and functions in atherosclerosis , 2020, Nature Reviews Cardiology.

[9]  Dave L Dixon,et al.  Interleukin‐1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST‐Segment–Elevation Myocardial Infarction , 2020, Journal of the American Heart Association.

[10]  R. Diaz,et al.  Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. , 2019, The New England journal of medicine.

[11]  Nicolas F. Fernandez,et al.  Single-cell immune landscape of human atherosclerotic plaques , 2019, Nature Medicine.

[12]  M. Jaafari,et al.  Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system. , 2019, Atherosclerosis.

[13]  Ira Tabas,et al.  Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities , 2019, Nature Reviews Cardiology.

[14]  D. Tsiantoulas,et al.  The role of B cells in atherosclerosis , 2018, Nature Reviews Cardiology.

[15]  U. de Faire,et al.  Interleukin 6 trans-signalling and risk of future cardiovascular events , 2018, Cardiovascular research.

[16]  C. Glass,et al.  Oxidized Phospholipids are Proinflammatory and Proatherogenic in Hypercholesterolemic Mice , 2018, Nature.

[17]  R. Morishita,et al.  Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice , 2018, PloS one.

[18]  Z. Mallat,et al.  NLRP3 inflammasome pathways in atherosclerosis. , 2017, Atherosclerosis.

[19]  G. Hansson.  Inflammation and Atherosclerosis: The End of a Controversy. , 2017, Circulation.

[20]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[21]  P. Shah,et al.  Identification of apoB‐100 Peptide‐Specific CD8+ T Cells in Atherosclerosis , 2017, Journal of the American Heart Association.

[22]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[23]  Matthew A. Cooper,et al.  Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice , 2017, Science.

[24]  P. Ridker.  How Common Is Residual Inflammatory Risk? , 2017, Circulation research.

[25]  B. Amundsen,et al.  Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. , 2016, European heart journal.

[26]  A. Thrift,et al.  Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). , 2016, American heart journal.

[27]  J. Witztum,et al.  Innate sensing of oxidation-specific epitopes in health and disease , 2016, Nature Reviews Immunology.

[28]  B. Hedblad,et al.  Low Levels of Apolipoprotein B-100 Autoantibodies Are Associated With Increased Risk of Coronary Events , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[29]  C. Macintyre,et al.  Acute myocardial infarction and influenza: a meta-analysis of case–control studies , 2015, Heart.

[30]  N. van Bruggen,et al.  FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. , 2015, JACC. Cardiovascular imaging.

[31]  P. Shah,et al.  Vaccine for atherosclerosis. , 2014, Journal of the American College of Cardiology.

[32]  S. Pucci,et al.  PTX3: a modulator of human coronary plaque vulnerability acting by macrophages type 2. , 2014, International journal of cardiology.

[33]  P. Ridker,et al.  Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. , 2014, Journal of the American College of Cardiology.

[34]  J. Sidney,et al.  Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100 , 2013, Front. Immunol..

[35]  N. Leitinger,et al.  Phenotypic polarization of macrophages in atherosclerosis. , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[36]  A. Tedgui,et al.  Regulatory T-Cell Response to Apolipoprotein B100–Derived Peptides Reduces the Development and Progression of Atherosclerosis in Mice , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[37]  P. Shah,et al.  CD8+ T Cells Mediate the Athero-Protective Effect of Immunization with an ApoB-100 Peptide , 2012, PloS one.

[38]  Michael J. Bevan,et al.  CD8+ T Cells: Foot Soldiers of the Immune System , 2011, Immunity.

[39]  H. Björkbacka,et al.  Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine , 2011, Journal of internal medicine.

[40]  P. Tipping,et al.  Conventional B2 B Cell Depletion Ameliorates whereas Its Adoptive Transfer Aggravates Atherosclerosis , 2010, The Journal of Immunology.

[41]  P. Subbaiah,et al.  Oxidized LDL: diversity, patterns of recognition, and pathophysiology. , 2010, Antioxidants & redox signaling.

[42]  R. Klingenberg,et al.  Intranasal Immunization With an Apolipoprotein B-100 Fusion Protein Induces Antigen-Specific Regulatory T Cells and Reduces Atherosclerosis , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[43]  K. Moore,et al.  NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease , 2010, Nature.

[44]  H. Björkbacka,et al.  Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B‐100 transgenic mice without inducing an increase in peptide‐specific antibodies , 2008, Journal of internal medicine.

[45]  A. Hamsten,et al.  High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. , 2008, European heart journal.

[46]  G. Hansson,et al.  Autoimmunity in atherosclerosis: a protective response losing control? , 2008, Journal of internal medicine.

[47]  G. Sangiorgi,et al.  Role of Inflammation in Atherosclerosis* , 2007, Journal of Nuclear Medicine.

[48]  M. Bennett,et al.  DNA damage and repair in atherosclerosis. , 2006, Cardiovascular research.

[49]  A. Tedgui,et al.  Cytokines in atherosclerosis: pathogenic and regulatory pathways. , 2006, Physiological reviews.

[50]  T. Henry,et al.  Extracellular Proteases in Atherosclerosis and Restenosis , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[51]  Elena Bonanno,et al.  Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction. , 2005, Journal of the American College of Cardiology.

[52]  P. Shah,et al.  Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression , 2005 .

[53]  Jan Nilsson,et al.  Recombinant Human Antibodies Against Aldehyde-Modified Apolipoprotein B-100 Peptide Sequences Inhibit Atherosclerosis , 2004, Circulation.

[54]  K. Walsh,et al.  Impaired Clearance of Apoptotic Cells Promotes Synergy between Atherogenesis and Autoimmune Disease , 2004, The Journal of experimental medicine.

[55]  Qingbo Xu,et al.  Autoimmune and inflammatory mechanisms in atherosclerosis. , 2004, Annual review of immunology.

[56]  P. Henkart,et al.  Perforin and the granule exocytosis cytotoxicity pathway. , 2003, Current opinion in immunology.

[57]  K. Maki,et al.  The safety and immunogenicity of a CETP vaccine in healthy adults. , 2003, Atherosclerosis.

[58]  J. Witztum,et al.  Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL , 2003, Nature Medicine.

[59]  Qingbo Xu,et al.  Cross-Reactive B-Cell Epitopes of Microbial and Human Heat Shock Protein 60/65 in Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[60]  G. Berglund,et al.  Identification of Immune Responses Against Aldehyde-Modified Peptide Sequences in ApoB Associated With Cardiovascular Disease , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[61]  B. Rollins,et al.  MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. , 1999, The Journal of clinical investigation.

[62]  P. Shah,et al.  Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits. , 1997, Journal of the American College of Cardiology.

[63]  P. Shah,et al.  Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[64]  D. Collen,et al.  Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. , 1995, The Journal of clinical investigation.

[65]  J. Witztum,et al.  T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[66]  E. Miller,et al.  Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[67]  R. Giscombe,et al.  Induction of T-cell activation by oxidized low density lipoprotein. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[68]  G. Hansson,et al.  Detection of activated T lymphocytes in the human atherosclerotic plaque. , 1989, The American journal of pathology.

[69]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[70]  J L Witztum,et al.  Low density lipoprotein undergoes oxidative modification in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[71]  P. Tipping,et al.  Follicular B Cells Promote Atherosclerosis via T Cell–Mediated Differentiation Into Plasma Cells and Secreting Pathogenic Immunoglobulin G , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[72]  P. Mohanty,et al.  A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous revascularization. , 2016, Journal of vascular surgery.

[73]  E. Dennis,et al.  Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. , 1999, The Journal of clinical investigation.